Adult Dosing
Attention deficit disorder with hyperactivity
- Start: 5 mg/day PO bid, increase dose in increments of 5 mg/day qwk
Obesity
Note: Administer 30 min before meals and avoid exceeding therapy few weeks after duration
Pediatric Dosing
Attention deficit disorder with hyperactivity
- >6 yrs
- Start: 5 mg/day PO bid, increase dose in increments of 5 mg/day qwk
Obesity
Note: Administer 30 min before meals and avoid exceeding therapy few weeks after duration
[Outline]
See Supplemental Patient Information
- Once the tolerance to anorectic effect develops, do not exceed the recommended dose in an attempt to increase the effect; rather, discontinue the drug
- Sudden death has been reported with CNS stimulant treatment in children and adolescents with structural cardiac abnormalities or other serious heart problems. Hence do not administer methamphetamine in these patients
- Adults with structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems should not be treated with stimulant drug, as sudden death, stroke and myocardial infarction have been reported in these patients when treated with stimulant drugs at usual doses for ADHD
- Stimulant drug can cause modest increase in average blood pressure and heart rate, monitor all patients for larger changes in heart rate and blood pressure and use cautiously in patients with underlying medical conditions like pre-existing hypertension, heart failure, recent myocardial infarction, or ventricular arrhythmia
- Take proper history and perform physical examination to assess the presence of cardiac disease in all the patients who are being considered for treatment with stimulant medications
- Perform prompt cardiac evaluation if patient develops symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during stimulant treatment
- Exacerbation of symptoms of behavior disturbance and thought disorder have been reported with stimulant medications
- Adequately screen the patients with comorbid depressive symptoms, to determine if they are at risk for bipolar disorder, before initiating treatment with a stimulant, as stimulant drugs can induce mixed/manic episode in such patients
- Psychotic or manic symptoms such as hallucinations, delusional thinking, or mania in children and adolescents have been reported with stimulants at usual doses without a prior history of psychotic illness or mania. Discontinue the treatment if such symptoms occurs
- Stimulants can cause aggressive behavior or hostility, hence monitor all patients beginning with stimulant treatment for ADHD for the appearance of or worsening of aggressive behavior or hostility
- Suppression of growth has been reported with amphetamines, hence monitor the growth during treatment with stimulants, interrupt the treatment in patients who are not growing or gaining height or weight as expected
- Treatment with stimulants lowers the convulsive threshold in patients with prior history of seizures, or prior EEG abnormalities in absence of seizures and rarely in patients without a history of seizures and no prior EEG evidence of seizures. Discontinue the drug in the presence of seizures
- Stimulants can cause difficulties with accommodation and blurring of vision
- Do not use methamphetamine to combat fatigue or to replace rest in normal persons
- To minimize the possibility of overdosage, limit the prescribing and dispensing of methamphetamine to the smallest amount that is feasible at one time
- Stimulants used to treat ADHD are associated with peripheral vasculopathy, including Raynaud’s phenomenon
Cautions: Use cautiously in
- Risk of cardiovascular diseases
- Mild hypertension
- Pre-existing psychotic disorder
- Bipolar disorder
- History or risk of seizure
- Tourette’s syndrome
Supplemental Patient Information
- Patients should be cautioned against engaging in potentially hazardous activities requiring alertness, such as operating machinery or driving a vehicle
- Inform patients, their families, and their caregivers about the potential benefits and risks associated with this drug and counsel them in its appropriate use
Pregnancy Category:C
Breastfeeding: Due to less information, an alternate drug may be preferred, especially while nursing a newborn or preterm infant. Do not use as recreational drug by nursing mother because it impairs judgment and child abilities. Methamphetamine and its metabolite have been detected in nursing infant serum after abuse of methamphetamine by nursing mothers. Nursing mother should Withhold the breastfeeding for 24-48 hrs after receiving the drugs. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 20 April 2011). Manufacturer advices caution.
US Trade Name(s)
US Availability
methamphetamine (generic)
Desoxyn
Canadian Trade Name(s)
Canadian Availability
UK Trade Name(s)
UK Availability
Australian Trade Name(s)
Australian Availability
[Outline]
Pricing data from www.DrugStore.com in U.S.A.
- Desoxyn 5 MG TABS [Bottle] (LUNDBECK)
20 mg = $107.99
30 mg = $161.98 - Methamphetamine HCl 5 MG TABS [Bottle] (MYLAN)
20 mg = $68.99
30 mg = $103.48
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
Drug Name: Desoxyn 5 MG Oral Tablet
Ingredient(s): Methamphetamine
Imprint: OV;12
Color(s): White
Shape: Round
Size (mm): 6.00
Score: 1
Inactive Ingredient(s): starch, corn / lactose / aminobenzoate sodium / stearic acid / talc
Drug Label Author:
Lundbeck Inc.
DEA Schedule:
CII
Drug Name: Methamphetamine Hydrochloride 5 MG Oral Tablet
Ingredient(s): Methamphetamine
Imprint: 115
Color(s): White
Shape: Round
Size (mm): 6.00
Score: 1
Inactive Ingredient(s): starch, corn / lactose monohydrate / stearic acid / talc
Drug Label Author:
Mylan Pharmaceuticals Inc.
DEA Schedule:
CII